TrialSignal
Clinical trial intelligence report
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07100067-Jul 28, 2026
NCT ID
NCT07100067
Status
RECRUITING
Phase
NA
Sponsor
Nanjing Legend Biotech Co.
Executive brief
Investment-Ready Snapshot
A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma. is a NA clinical asset sponsored by Nanjing Legend Biotech Co. in Relapsed/Refractory Multiple Myeloma(MM). SEO and diligence focus: LCAR- F33S cells intravenous infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07100067
Indication
Relapsed/Refractory Multiple Myeloma(MM)
Modality
protein therapy
Target
LCAR- F33S cells intravenous infusion
Intervention
LCAR- F33S cells intravenous infusion
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.